Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers.
about
Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infectionThird trimester antiviral therapy for preventing recurrent genital herpes at deliveryProgress and problems in understanding and managing primary Epstein-Barr virus infectionsImpact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infectionAntiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapyMolecular Basis of Prodrug Activation by Human Valacyclovirase, an -Amino Acid Ester HydrolaseComparison of efficacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murine immunosuppression modelAcyclovir Therapy Reduces the CD4+ T Cell Response against the Immunodominant pp65 Protein from Cytomegalovirus in Immune Competent IndividualsInfant safety during and after maternal valacyclovir therapy in conjunction with antiretroviral HIV-1 prophylaxis in a randomized clinical trialA randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.Antiviral selection in the management of acute retinal necrosis.Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal functionPharmacokinetics of amino acid ester prodrugs of acyclovir after oral administration: interaction with the transporters on Caco-2 cells.Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease.Valacyclovir and acyclovir pharmacokinetics in immunocompromised children.Controlled ex-vivo plasma hydrolysis of valaciclovir to acyclovir demonstration using tandem mass spectrometry.Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapyValaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study GroupValaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study GroupEmerging drugs for varicella-zoster virus infections.Inhibition of dengue virus by an ester prodrug of an adenosine analog.Novel agents for the therapy of varicella-zoster virus infections.Multiple interactions of cimetidine and probenecid with valaciclovir and its metabolite acyclovirResistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and managementDevelopment and characterization of a novel mouse line humanized for the intestinal peptide transporter PEPT1Valacyclovir in the treatment of acute retinal necrosis.Peptide therapeutics for treating ocular surface infectionsThe development of orally administrable gemcitabine prodrugs with D-enantiomer amino acids: enhanced membrane permeability and enzymatic stabilityHigh-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies.Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir.Clinical manifestations and treatment considerations of herpes simplex virus infection.Valacyclovir for herpes simplex encephalitis.Consistent inhibition of HIV-1 replication in CD4+ T cells by acyclovir without detection of human herpesviruses.Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adultsAbsolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans.Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy.Comparison of effects of famciclovir and valaciclovir on pathogenesis of herpes simplex virus type 2 in a murine infection modelAcyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir.A review of famciclovir in the management of genital herpes.Synthesis and characterization of a new Peptide prodrug of glucosamine with enhanced gut permeability.
P2860
Q24242853-FB6848C0-4BA8-4340-8C42-9BE550FE6D2CQ24246421-8F484F21-BEC9-4015-BB94-BA59A4EFEE30Q24597706-57E5F89D-7560-4C00-BF61-1E001CE353ADQ24671668-15A31B7E-D767-426F-AF92-87E2FF79A208Q24672068-B94BC347-E103-44DB-9B05-4CDE0477B0CEQ27649800-CD67B62D-430E-401E-B6C7-CD083F4026A8Q28367893-3D75A7A9-4AC6-45F7-A0D6-ED088511DC84Q28546851-3B7D6A77-29EF-4CE9-A7D1-E219821AF956Q28730640-8BC94351-1434-4653-AE5E-7A4F64CE3AE4Q33345650-3AC9A90F-EEBF-4DB0-84FD-464356159CBEQ33644146-B71C2581-1FB9-47D7-8DE9-00C52A14A45AQ33676105-CAAEED6B-6835-4305-BBF6-503EDADBA7E4Q33697974-28E27A87-1944-4CC0-8438-E7C3B0DECA19Q33754585-84295A74-EA1F-42C7-A834-8F7700AFB5A5Q33776931-D6590CE7-92E1-41B2-8624-AF92EB4837E8Q33844972-DB431B1C-EC9E-4069-B4DC-D66CA601B579Q33884052-71DEA837-3FAF-46FF-9E5B-BA195F10FBF6Q33936572-72C3A318-4450-4BD1-ABA1-86D8433CAD1AQ33936578-ED97B2A3-94A8-4090-9480-B58F34E4B654Q34027426-256213D5-1C92-4AB2-B2D1-C259C0F16DCAQ34045313-B54A5AEC-7DD7-4315-BAF2-D74608369F07Q34074994-B86AE005-BE5C-4B3A-B510-C9DA7EBD2CEAQ34109825-E6D51D23-F723-499E-B96B-77956DEF59AFQ34149904-E15B399E-285F-4EDF-B818-57BC9546D8B1Q34293583-67C41CC2-C89E-4B90-B828-FAD67385DBFCQ34403015-404F7B93-416E-4D3E-A822-D9D30A52D342Q34454864-A3ECFCBF-D231-49A2-9FE0-CD58F6A5548BQ34570055-B7C47690-984F-4DCC-8972-7F06815D5F1CQ34734868-50109FED-10DB-4678-9421-290BB4155F7DQ34918273-186600E4-0F9D-4653-B420-704684C0805FQ34918343-50ED4EB5-BF18-45B8-8DF0-37922488391DQ35065826-A61A1B1D-1D76-4902-925E-455CEF61F67AQ35076929-79E53286-C5E7-4AC6-9B63-A65B274C489BQ35116285-072F3E8A-A46F-42F8-9CB2-E7166530B85AQ35120940-DCED881F-57D1-4BC7-8C7D-EACB41A347E6Q35121549-1F691CC0-1B29-470A-998F-EA790604181DQ35123563-9359CAE3-AE0C-4C94-A381-EC7A9FED0C0BQ35166138-8B049587-2D22-4ED3-AED6-B872135D24E3Q35615364-3E290363-A235-40BE-8496-86DBB7801183Q35632646-5A77B181-60B7-44E5-B84F-21DA9E38E180
P2860
Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers.
description
1993 nî lūn-bûn
@nan
1993 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Pharmacokinetics of the acyclo ...... stration to normal volunteers.
@ast
Pharmacokinetics of the acyclo ...... stration to normal volunteers.
@en
Pharmacokinetics of the acyclo ...... stration to normal volunteers.
@nl
type
label
Pharmacokinetics of the acyclo ...... stration to normal volunteers.
@ast
Pharmacokinetics of the acyclo ...... stration to normal volunteers.
@en
Pharmacokinetics of the acyclo ...... stration to normal volunteers.
@nl
prefLabel
Pharmacokinetics of the acyclo ...... stration to normal volunteers.
@ast
Pharmacokinetics of the acyclo ...... stration to normal volunteers.
@en
Pharmacokinetics of the acyclo ...... stration to normal volunteers.
@nl
P2093
P356
P1476
Pharmacokinetics of the acyclo ...... stration to normal volunteers.
@en
P2093
Burnette T
Cederberg DM
Doucette M
de Miranda P
P304
P356
10.1038/CLPT.1993.196
P407
P577
1993-12-01T00:00:00Z